Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Pharmacokinetics and Safety of Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

NCT07055412 is registered in ClinicalTrials.gov with Neurodawn Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07055412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Pharmacokinetics and Safety of Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 10, 2025
Completion date
December 31, 2025
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mild hepatic insufficiency, moderate hepatic insufficiency, normal hepatic function, pharmacokinetic differences, saftey, y-3